Cargando…

Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis

In contrast to patients with viral hepatitis, patients with nonalcoholic fatty liver disease (NAFLD) can progress to hepatocellular carcinoma during the initial stages of liver fibrosis. Development and implementation of noninvasive methods for diagnosis and progression prediction are important for...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamada, Yoshihiro, Ono, Masafumi, Hyogo, Hideyuki, Fujii, Hideki, Sumida, Yoshio, Yamada, Makoto, Mori, Kojiroh, Tanaka, Saiyu, Maekawa, Tomohiro, Ebisutani, Yusuke, Yamamoto, Akiko, Takamatsu, Shinji, Yoneda, Masashi, Kawada, Norifumi, Chayama, Kazuaki, Saibara, Toshiji, Takehara, Tetsuo, Miyoshi, Eiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678915/
https://www.ncbi.nlm.nih.gov/pubmed/29404494
http://dx.doi.org/10.1002/hep4.1080
_version_ 1783277536436813824
author Kamada, Yoshihiro
Ono, Masafumi
Hyogo, Hideyuki
Fujii, Hideki
Sumida, Yoshio
Yamada, Makoto
Mori, Kojiroh
Tanaka, Saiyu
Maekawa, Tomohiro
Ebisutani, Yusuke
Yamamoto, Akiko
Takamatsu, Shinji
Yoneda, Masashi
Kawada, Norifumi
Chayama, Kazuaki
Saibara, Toshiji
Takehara, Tetsuo
Miyoshi, Eiji
author_facet Kamada, Yoshihiro
Ono, Masafumi
Hyogo, Hideyuki
Fujii, Hideki
Sumida, Yoshio
Yamada, Makoto
Mori, Kojiroh
Tanaka, Saiyu
Maekawa, Tomohiro
Ebisutani, Yusuke
Yamamoto, Akiko
Takamatsu, Shinji
Yoneda, Masashi
Kawada, Norifumi
Chayama, Kazuaki
Saibara, Toshiji
Takehara, Tetsuo
Miyoshi, Eiji
author_sort Kamada, Yoshihiro
collection PubMed
description In contrast to patients with viral hepatitis, patients with nonalcoholic fatty liver disease (NAFLD) can progress to hepatocellular carcinoma during the initial stages of liver fibrosis. Development and implementation of noninvasive methods for diagnosis and progression prediction are important for effective NAFLD surveillance. Mac‐2 binding protein (Mac‐2bp) is a useful nonalcoholic steatohepatitis (NASH) diagnosis biomarker and a powerful prediction biomarker for NAFLD fibrosis stage. Wisteria floribunda agglutinin (WFA)‐positive Mac‐2bp (WFA(+)‐M2BP) is a novel serum fibrosis biomarker for chronic hepatitis C that has clinical validity. Mac‐2bp and WFA(+)‐M2BP are also clinical NAFLD biomarker candidates. We examined the efficacy of Mac‐2bp and WFA(+)‐M2BP for NAFLD assessment using patients with biopsy‐proven NAFLD (n = 510; NAFLD cohort) and subjects who received a health check‐up (n = 2,122; check‐up cohort). In the NAFLD cohort, we set the fibrosis predicting cutoff values as 1.80 (F1), 2.21 (F2), and 2.24 μg/mL (F3). In the subjects with fatty liver from the check‐up cohort (n = 1,291), the serum Mac‐2bp levels were >1.80 μg/mL in 38.6% of the subjects (n = 498), and >2.24 μg/mL in 24.6% of the subjects (n = 318). The NAFLD cohort results indicated that Mac‐2bp and WFA(+)‐M2BP were equally useful for NASH diagnosis. During the early stages of fibrosis (F1, F2), the increase in Mac‐2bp was statistically significant but WFA(+)‐M2BP did not increase. Logistic regression analysis revealed that Mac‐2bp was an independent determinant for the prediction of advanced fibrosis stage (≥F2), even when adjusted for WFA(+)‐M2BP. Immunohistochemical staining of Mac‐2bp revealed that hepatocytes strongly expressed Mac‐2bp in patients with NAFLD. Conclusion: Our results indicated that hepatocyte‐derived Mac‐2bp would be a useful single biomarker for NASH diagnosis and fibrosis stage prediction in patients with NAFLD. (Hepatology Communications 2017;1:780–791)
format Online
Article
Text
id pubmed-5678915
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56789152018-02-05 Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis Kamada, Yoshihiro Ono, Masafumi Hyogo, Hideyuki Fujii, Hideki Sumida, Yoshio Yamada, Makoto Mori, Kojiroh Tanaka, Saiyu Maekawa, Tomohiro Ebisutani, Yusuke Yamamoto, Akiko Takamatsu, Shinji Yoneda, Masashi Kawada, Norifumi Chayama, Kazuaki Saibara, Toshiji Takehara, Tetsuo Miyoshi, Eiji Hepatol Commun Original Articles In contrast to patients with viral hepatitis, patients with nonalcoholic fatty liver disease (NAFLD) can progress to hepatocellular carcinoma during the initial stages of liver fibrosis. Development and implementation of noninvasive methods for diagnosis and progression prediction are important for effective NAFLD surveillance. Mac‐2 binding protein (Mac‐2bp) is a useful nonalcoholic steatohepatitis (NASH) diagnosis biomarker and a powerful prediction biomarker for NAFLD fibrosis stage. Wisteria floribunda agglutinin (WFA)‐positive Mac‐2bp (WFA(+)‐M2BP) is a novel serum fibrosis biomarker for chronic hepatitis C that has clinical validity. Mac‐2bp and WFA(+)‐M2BP are also clinical NAFLD biomarker candidates. We examined the efficacy of Mac‐2bp and WFA(+)‐M2BP for NAFLD assessment using patients with biopsy‐proven NAFLD (n = 510; NAFLD cohort) and subjects who received a health check‐up (n = 2,122; check‐up cohort). In the NAFLD cohort, we set the fibrosis predicting cutoff values as 1.80 (F1), 2.21 (F2), and 2.24 μg/mL (F3). In the subjects with fatty liver from the check‐up cohort (n = 1,291), the serum Mac‐2bp levels were >1.80 μg/mL in 38.6% of the subjects (n = 498), and >2.24 μg/mL in 24.6% of the subjects (n = 318). The NAFLD cohort results indicated that Mac‐2bp and WFA(+)‐M2BP were equally useful for NASH diagnosis. During the early stages of fibrosis (F1, F2), the increase in Mac‐2bp was statistically significant but WFA(+)‐M2BP did not increase. Logistic regression analysis revealed that Mac‐2bp was an independent determinant for the prediction of advanced fibrosis stage (≥F2), even when adjusted for WFA(+)‐M2BP. Immunohistochemical staining of Mac‐2bp revealed that hepatocytes strongly expressed Mac‐2bp in patients with NAFLD. Conclusion: Our results indicated that hepatocyte‐derived Mac‐2bp would be a useful single biomarker for NASH diagnosis and fibrosis stage prediction in patients with NAFLD. (Hepatology Communications 2017;1:780–791) John Wiley and Sons Inc. 2017-08-16 /pmc/articles/PMC5678915/ /pubmed/29404494 http://dx.doi.org/10.1002/hep4.1080 Text en © 2017 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Kamada, Yoshihiro
Ono, Masafumi
Hyogo, Hideyuki
Fujii, Hideki
Sumida, Yoshio
Yamada, Makoto
Mori, Kojiroh
Tanaka, Saiyu
Maekawa, Tomohiro
Ebisutani, Yusuke
Yamamoto, Akiko
Takamatsu, Shinji
Yoneda, Masashi
Kawada, Norifumi
Chayama, Kazuaki
Saibara, Toshiji
Takehara, Tetsuo
Miyoshi, Eiji
Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis
title Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis
title_full Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis
title_fullStr Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis
title_full_unstemmed Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis
title_short Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis
title_sort use of mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678915/
https://www.ncbi.nlm.nih.gov/pubmed/29404494
http://dx.doi.org/10.1002/hep4.1080
work_keys_str_mv AT kamadayoshihiro useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT onomasafumi useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT hyogohideyuki useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT fujiihideki useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT sumidayoshio useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT yamadamakoto useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT morikojiroh useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT tanakasaiyu useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT maekawatomohiro useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT ebisutaniyusuke useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT yamamotoakiko useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT takamatsushinji useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT yonedamasashi useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT kawadanorifumi useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT chayamakazuaki useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT saibaratoshiji useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT takeharatetsuo useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT miyoshieiji useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis
AT useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis